Progressive Fibrosing Interstitial Lung Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration
Progressive Fibrosing Interstitial Lung Disease Overview
Progressive fibrosing interstitial lung diseases (PF-ILD) consist of a diverse group of interstitial lung diseases (ILD) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality.
“Progressive Fibrosing Interstitial Lung Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Progressive Fibrosing Interstitial Lung Disease Market.
The Progressive Fibrosing Interstitial Lung Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Progressive Fibrosing Interstitial Lung Disease Pipeline Report:
- Companies across the globe are diligently working toward developing novel Progressive Fibrosing Interstitial Lung Disease treatment therapies with a considerable amount of success over the years. Progressive Fibrosing Interstitial Lung Disease Key players such as – Boehringer Ingelheim, FibroGen, Bristol-Myers Squibb, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, and others, are developing therapies for the Progressive Fibrosing Interstitial Lung Disease treatment
- Progressive Fibrosing Interstitial Lung Disease Emerging therapies such as – BI 1015550, Pamrevlumab, BMS-986278, PRM-151 (RG6354), PLN-74809, Tyvaso (treprostinil), and others are expected to have a significant impact on the Progressive Fibrosing Interstitial Lung Disease market in the coming years.
- In September 2021, the FDA approved the use of Ofev (nintedanib) for the treatment of PF-ILD.
- In August 2021, a phase III clinical trial evaluating the efficacy and safety of the investigational drug pamrevlumab in the treatment of PF-ILD met its primary endpoint, demonstrating significant improvement in forced vital capacity (FVC) compared to placebo.
- In May 2021, a phase III clinical trial evaluating the efficacy and safety of the investigational drug nintedanib in the treatment of PF-ILD met its primary endpoint, demonstrating significant reduction in the rate of FVC decline compared to placebo.
Progressive Fibrosing Interstitial Lung Disease Pipeline Therapeutics Assessment
- Progressive Fibrosing Interstitial Lung Disease Assessment by Product Type
- Progressive Fibrosing Interstitial Lung Disease By Stage and Product Type
- Progressive Fibrosing Interstitial Lung Disease Assessment by Route of Administration
- Progressive Fibrosing Interstitial Lung Disease By Stage and Route of Administration
- Progressive Fibrosing Interstitial Lung Disease Assessment by Molecule Type
- Progressive Fibrosing Interstitial Lung Disease by Stage and Molecule Type
DelveInsight’s Progressive Fibrosing Interstitial Lung Disease Report covers around 5+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Some of the key companies in the Progressive Fibrosing Interstitial Lung Disease Therapeutics Market include:
Key companies developing therapies for Progressive Fibrosing Interstitial Lung Disease treatment are – Boehringer Ingelheim Pharmaceuticals Inc., Bristol-Myers Squibb, Hoffmann-La Roche Ltd, FibroGen, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, and others
Emerging Progressive Fibrosing Interstitial Lung Disease Drugs Under Different Phases of Clinical Development Include:
- BI 1015550: Boehringer Ingelheim
- Pamrevlumab: FibroGen
- BMS-986278: Bristol-Myers Squibb
- PRM-151 (RG6354): Hoffmann-La Roche Ltd
- PLN-74809: Pliant Therapeutics, Inc
- Tyvaso (treprostinil): United Therapeutics
Get a Free Sample PDF Report to know more about Progressive Fibrosing Interstitial Lung Disease Pipeline Therapeutic Assessment-
Progressive Fibrosing Interstitial Lung Disease Pipeline Analysis:
The Progressive Fibrosing Interstitial Lung Disease pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Progressive Fibrosing Interstitial Lung Disease with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Progressive Fibrosing Interstitial Lung Disease Treatment.
- Progressive Fibrosing Interstitial Lung Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Progressive Fibrosing Interstitial Lung Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Progressive Fibrosing Interstitial Lung Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Progressive Fibrosing Interstitial Lung Disease product details are provided in the report. Download the Progressive Fibrosing Interstitial Lung Disease pipeline report to learn more about the emerging Progressive Fibrosing Interstitial Lung Disease therapies
Progressive Fibrosing Interstitial Lung Disease Pipeline Market Drivers
- Advancement in research and development
- Exponential Market Growth
- Potential biomarkers
- Improvement in the treatment pathways
Progressive Fibrosing Interstitial Lung Disease Pipeline Market Barriers
- Dry clinical pipeline for Non-IPF PFIILD
- Diagnostic Barrier
- Disease understanding challenges
- Pitfalls of epidemiological studies in ILDs
Scope of Progressive Fibrosing Interstitial Lung Disease Pipeline Drug Insight
- Coverage: Global
- Key Progressive Fibrosing Interstitial Lung Disease Companies: Boehringer Ingelheim, FibroGen, Bristol-Myers Squibb, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, and others
- Key Progressive Fibrosing Interstitial Lung Disease Therapies: BI 1015550, Pamrevlumab, BMS-986278, PRM-151 (RG6354), PLN-74809, Tyvaso (treprostinil), and others
- Progressive Fibrosing Interstitial Lung Disease Therapeutic Assessment: Progressive Fibrosing Interstitial Lung Disease current marketed and Progressive Fibrosing Interstitial Lung Disease emerging therapies
- Progressive Fibrosing Interstitial Lung Disease Market Dynamics: Progressive Fibrosing Interstitial Lung Disease market drivers and Progressive Fibrosing Interstitial Lung Disease market barriers
Request for Sample PDF Report for Progressive Fibrosing Interstitial Lung Disease Pipeline Assessment and clinical trials
Table of Contents
|
1 |
Progressive Fibrosing Interstitial Lung Disease Report Introduction |
|
2 |
Progressive Fibrosing Interstitial Lung Disease Executive Summary |
|
3 |
Progressive Fibrosing Interstitial Lung Disease Overview |
|
4 |
Progressive Fibrosing Interstitial Lung Disease- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Progressive Fibrosing Interstitial Lung Disease Pipeline Therapeutics |
|
6 |
Progressive Fibrosing Interstitial Lung Disease Late Stage Products (Phase II/III) |
|
7 |
Progressive Fibrosing Interstitial Lung Disease Mid Stage Products (Phase II) |
|
8 |
Progressive Fibrosing Interstitial Lung Disease Early Stage Products (Phase I) |
|
9 |
Progressive Fibrosing Interstitial Lung Disease Preclinical Stage Products |
|
10 |
Progressive Fibrosing Interstitial Lung Disease Therapeutics Assessment |
|
11 |
Progressive Fibrosing Interstitial Lung Disease Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Progressive Fibrosing Interstitial Lung Disease Key Companies |
|
14 |
Progressive Fibrosing Interstitial Lung Disease Key Products |
|
15 |
Progressive Fibrosing Interstitial Lung Disease Unmet Needs |
|
16 |
Progressive Fibrosing Interstitial Lung Disease Market Drivers and Barriers |
|
17 |
Progressive Fibrosing Interstitial Lung Disease Future Perspectives and Conclusion |
|
18 |
Progressive Fibrosing Interstitial Lung Disease Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Progressive Fibrosing Interstitial Lung Disease drugs and therapies
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com
